U of A Research Uncovers Anti-Obesity Drug’s Potential to Enhance Heart Function
GDF15 is an anti-obesity drug currently in human clinical trials. Research indicates it may improve heart health in obese mice beyond what weight loss can achieve.
John Ussher, a professor at the University of Alberta and a Canada Research Chair in Pharmacotherapy of Energy Metabolism in Obesity, leads this study. His team studied two groups of obese mice with Type 2 diabetes. One group received GDF15, while the other followed a controlled food diet. Both groups lost weight, but the GDF15-treated mice showed better improvements in heart function.
Ussher emphasized that both groups had equal weight loss, yet the GDF15 group had superior diastolic heart function improvement. Diastolic dysfunction occurs when the heart struggles to relax, leading to insufficient blood filling.
Diabetes patients face more than double the risk of heart disease compared to those without diabetes. Heart disease is a leading cause of death in people with Type 2 diabetes. Diastolic dysfunction often goes undiagnosed and asymptomatic in these patients, delaying treatment until significant damage has occurred.
How does diastolic dysfunction affect heart failure risk in obese individuals with Type 2 diabetes?
Interview with John Ussher: Insights into GDF15 and Its Impact on Heart Health in Obese Diabetes Patients
Interviewer: Thank you for joining us, Professor Ussher. Your team’s research on GDF15 is receiving significant attention. Can you start by explaining what GDF15 is and its role as an anti-obesity treatment?
John Ussher: Thank you for having me. GDF15, or Growth Differentiation Factor 15, is a protein that has shown promise as an anti-obesity drug currently undergoing human clinical trials. Our research indicates that, apart from promoting weight loss, GDF15 may have unique properties that enhance heart health, particularly in individuals with obesity and Type 2 diabetes.
Interviewer: Your study focused on two groups of obese mice with Type 2 diabetes—one receiving GDF15 and the other on a controlled diet. What were your key findings in terms of heart function?
John Ussher: Both groups exhibited weight loss, but significantly, the mice treated with GDF15 demonstrated more pronounced improvements in diastolic heart function. This is notable because diastolic dysfunction—when the heart has difficulty relaxing and filling with blood—can lead to serious heart problems. The GDF15 group not only managed their weight but also showed enhanced heart recovery that weight loss alone couldn’t achieve.
Interviewer: That’s intriguing. Can you elaborate on why diastolic dysfunction is a concern, especially in diabetes patients?
John Ussher: Absolutely. Patients with diabetes face more than double the risk of developing heart disease compared to those without the condition. Diastolic dysfunction is particularly insidious because it often goes undiagnosed—many individuals might not exhibit symptoms until significant heart damage has occurred. Common signs like fatigue and shortness of breath can easily be attributed to other issues, leading to delays in critical treatment.
Interviewer: In your opinion, how does diastolic heart dysfunction progress in diabetic patients?
John Ussher: Well, it’s a gradual process. For instance, a 45-year-old diabetic may find climbing stairs manageable, but by 65, the same individual could struggle due to worsening diastolic dysfunction. This progression is alarming, as diastolic heart failure accounts for about half of all heart failure cases, making early intervention crucial.
Interviewer: What are your next steps in understanding the implications of diastolic dysfunction for diabetic patients?
John Ussher: Our goal is to assess whether early signs of diastolic dysfunction in obese patients with Type 2 diabetes may escalate their risk of heart failure later in life. By identifying these early markers, we hope to implement preventative measures that can significantly reduce heart failure incidence among the elderly with Type 2 diabetes.
Interviewer: Thank you for your insights, Professor Ussher. Your research is vital in addressing the complexities of heart health in diabetes patients, and we look forward to seeing the outcome of your further studies.
John Ussher: Thank you. It’s important work, and I’m glad to share it with you and your audience.
Symptoms like fatigue and shortness of breath may point to diastolic dysfunction, but they are often overlooked. As a result, many patients do not discover their heart issues until they have lived with diabetes for 10 to 20 years, possibly progressing to diastolic heart failure.
In diastolic heart failure, blood may back up in the lungs. Ussher argues that a diabetic patient at age 45 can manage stairs easily. However, at 65, with the same condition worsening, they may struggle to walk up those stairs. Diastolic heart failure affects about half of all heart failure cases.
Ussher aims to determine if early signs of diastolic dysfunction in obese patients with Type 2 diabetes increase their heart failure risk later in life. He seeks insights to make preventative changes that could significantly reduce heart failure among the elderly with Type 2 diabetes.